PDB42 INCRETIN-THERAPY IN ADDITION TO METFORMIN AND/OR SULFONYLUREA FOR TYPE 2 DIABETES MELLITUS (T2DM)- COSTEFFECTIVENESS OF LIRAGLUTIDE VERSUS EXENATIDE FROM THE PERSPECTIVE OF THE GERMAN STATUTORY HEALTH INSURANCE (SHI)
Nov 1, 2010, 00:00
10.1016/S1098-3015(11)72100-3
https://www.valueinhealthjournal.com/article/S1098-3015(11)72100-3/fulltext
Title :
PDB42 INCRETIN-THERAPY IN ADDITION TO METFORMIN AND/OR SULFONYLUREA FOR TYPE 2 DIABETES MELLITUS (T2DM)- COSTEFFECTIVENESS OF LIRAGLUTIDE VERSUS EXENATIDE FROM THE PERSPECTIVE OF THE GERMAN STATUTORY HEALTH INSURANCE (SHI)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)72100-3&doi=10.1016/S1098-3015(11)72100-3
First page :
A291
Section Title :
RESEARCH POSTER ABSTRACTS
Open access? :
No
Section Order :
258